Clinical evidence for orphan medicinal products-a cause for concern?
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 164
Abstract
The difficulties associated with organising clinical studies for orphan medicinal products (OMPs) are plentiful. Recent debate on the long-term effectiveness of some OMPs, led us to question whether the initial standards for clinical evidence for OMPs, set by the European Medicines Agency (EMA) at the time of marketing authorization, are too low. Therefore, the aim of this study was to quantitatively evaluate the characteristics and quality of clinical evidence that is presented for OMPs to obtain marketing authorization in Europe, using the new and validated COMPASS tool.Keywords
This publication has 29 references indexed in Scilit:
- Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brainOrphanet Journal of Rare Diseases, 2013
- Characteristics of orphan drug applications that fail to achieve marketing approval in the USADrug Discovery Today, 2011
- Benefits, challenges and obstacles of adaptive clinical trial designsOrphanet Journal of Rare Diseases, 2011
- Adaptive designs in clinical trialsPerspectives in Clinical Research, 2011
- A guide to the design and analysis of small clinical studiesPharmaceutical Statistics, 2010
- Access to orphan drugs despite poor quality of clinical evidenceBritish Journal of Clinical Pharmacology, 2010
- Rare diseases, orphan drugs and their regulation: questions and misconceptionsNature Reviews Drug Discovery, 2010
- Adequacy of health‐related quality of life measures in children under 5 years old: systematic reviewJournal of Advanced Nursing, 2007
- Orphan drugs revisitedQJM: An International Journal of Medicine, 2006
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996